The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Hematological Oncology Année : 2019

The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm

, (1) , , (2) , (3) , (4) , (5)
1
2
3
4
5

Résumé

We describe the use and value of a lenalidomide/bortezomib/dexamethasone regimen for the treatment of three patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN, a disease that lacks a consensus treatment). After five cycles of chemotherapy, we observed two complete responses and one clinical remission. Together with the encouraging literature data on the effects of lenalidomide and bortezomib on BPDCN cells, our results might prompt further investigations of this regimen's value in BPDCN.
Fichier non déposé

Dates et versions

hal-03605014 , version 1 (10-03-2022)

Identifiants

Citer

Vincent Marmouset, Magalie Joris, Lavinia Merlusca, Marie Beaumont, Amandine Charbonnier, et al.. The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm. Hematological Oncology, 2019, 37 (4), pp.487-489. ⟨10.1002/hon.2671⟩. ⟨hal-03605014⟩
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More